Link Between Plasma Aldosterone Levels and Cardiovascular Disease Risk in Patients with Hypertension
Overview
This study investigates the association between plasma aldosterone concentration (PAC) and incident cardiovascular disease (CVD) in hypertensive patients, excluding those with primary aldosteronism. Findings indicate that higher PAC levels correlate with an increased risk of CVD, suggesting PAC may be a target for early prevention.
Background
Understanding the relationship between aldosterone and cardiovascular disease is crucial, particularly in hypertensive patients who are at increased risk for adverse outcomes. Previous studies have shown conflicting results regarding the impact of aldosterone on CVD, highlighting the need for large-scale investigations that exclude primary aldosteronism. This study aims to clarify the role of PAC in cardiovascular risk stratification among hypertensive individuals.
Data Highlights
Quartile
Risk of CVD (HR)
Lowest
1.00
Highest
1.51 (95% CI 1.23–1.86)
Key Findings
A total of 8653 hypertensive patients were analyzed over a median follow-up of 5.2 years.
737 cases of incident CVD were recorded during the study period.
Higher quartiles of PAC were associated with increased risk of CVD.
Patients in the highest quartile of PAC had a 51% increased risk of CVD compared to those in the lowest quartile.
Results remained consistent across stratification and sensitivity analyses.
Clinical Implications
Clinicians should consider measuring PAC in hypertensive patients as part of cardiovascular risk assessment. The findings suggest that targeting elevated PAC levels may provide an opportunity for early intervention and prevention of cardiovascular events.
Conclusion
The study establishes a significant association between higher PAC and increased risk of CVD in hypertensive patients, indicating the potential for PAC to serve as a modifiable risk factor in this population.
